News | Heart Valve Technology | March 29, 2016

National Principal Investigators Named for NeoChord U.S. Pivotal Trial

Trial will assess NeoChord DS1000 system for minimally invasive repair of degenerative mitral valve regurgitation without cardiopulmonary bypass

NeoChord, U.S. pivotal trial, principal investigators, DS1000 system, degenerative mitral valve regurgitation, DMR

The NeoChord DS1000 (A) has the following features: A tip with expandable jaws to grasp the leaflet and four fiber-optic channels (B), each of which corresponds to an indicator light on the device monitor (C) to confirm proper leaflet capture. The needle (D) is also included in the device to deploy the suture after confirmation of leaflet capture. Image courtesy of NeoChord Inc.

March 29, 2016 — NeoChord Inc. announced that David H. Adams, M.D., and Michael A. Borger, M.D., Ph.D., will serve as national co-principal investigators of the company’s U.S. pivotal trial scheduled to commence later this year. The trial will study the NeoChord DS1000 system for minimally invasive repair of degenerative mitral valve regurgitation (DMR) without the use of cardiopulmonary bypass.

Adams is the Marie-Josée and Henry R. Kravis Professor and Chairman of the Department of Cardiovascular Surgery in the Icahn School of Medicine at Mount Sinai, and cardiac surgeon-in-chief of the Mount Sinai Health System. An acclaimed speaker, author, and renowned educator in the field of mitral valve reconstruction, Adams has given more than 350 invited lectures, authored more than 250 publications, and performed mitral valve surgery throughout the world. Over the past several years he has served as the national co-principal investigator of the Medtronic CoreValve U.S. Pivotal Trial. He is also a co-author with Prof. Alain Carpentier of the world’s widest selling textbook in mitral valve reconstruction.

Borger is professor of cardiothoracic surgery at Columbia Presbyterian School of Medicine, and the director of aortic surgery at the Cardiovascular Institute in the New York-Presbyterian/ Columbia University Medical Center. Previously, he served as professor and the associate director of the Leipzig Heart Center, the largest heart valve center in Europe. Borger is an internationally recognized leader in the fields of minimally invasive cardiac surgery, aortic surgery and novel surgical approaches to treat valvular heart disease. On the forefront of pioneering strategies to advance cardiac surgery throughout his career, he has published 250 contributions on a wide range of topics and served in numerous societal and academic journal leadership positions in both Europe and North America.

“To date, the NeoChord technology has demonstrated excellent outcomes from its commercial experience in Europe,” stated Adams. “I look forward to partnering with Dr. Borger as we initiate the U.S. pivotal trial for this cutting-edge technology.”

NeoChord received CE market clearance for the DS1000 system in December 2012. The device is not available for use in the United States.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init